increasing incidence of CKD in china, with the disease occurrence reaching around 10.8% in 2012, further intensifying incidence of ESRD. 3 Although a widely adopted renal replacement therapy-hemodialysis (HD) has been constantly improved with the growing insight into various HD complications, the prognosis of HD patients is still poor and the morbidity and mortality rates after HD treatment still remain high. 4, 5 Based on the fact that HD helps to remove the extracorporeal waste products such as toxins and free water in order to correct the electrolyte and acid-base imbalances, researchers are exploring valuable molecular targets to improve HD efficacy.
Although previous studies have demonstrated that cardiac troponin T, Brain natriuretic peptide (BNP), N-terminal-proBNP, and ferritin are all predictors of HD efficacy, their sensitivity and specificity
were not documented. 6, 7 More molecular markers for HD efficacy evaluation with high sensitivity and specificity might be of help for ESRD treatment.
CD62P, a glycoprotein stored in platelets and endothelial cells, can be transferred to the cell surface and released from platelets and endothelial cells by pro-thrombotic and inflammatory factors which were synthesized via the process of cell activation, thus promoting the accumulation of the various pro-coagulant factors and cells (platelets and leukocytes) leading to the formation of thrombus. 8 Correspondingly, increased CD62P level indicates greater inflammatory responses and thrombosis and is strongly associated with a blood hypercoagulable state which commonly occurs in patients with ESRD. 9 On the basis of the information provided above, it is concluded that CD62P acts as a key factor in the process of platelet aggregation and has become a marker for platelet activation to evaluate the progression of disease related with inflammation and thrombosis. 10 On the other hand, thrombospondin (TSP), another alpha-granule content in platelets, found on the surface of stimulated platelets, is subsequently recognized by its monoclonal antibody P10 to trigger the platelet aggregation process. 11 Hence, P10 could also be a platelet activation marker potentially reflecting disease progression. As markers of platelet activation, CD62p and P10 is very likely to be correlated with hypercoagulability, 12 which may provide a novel investigation option for HD efficacy evaluation. However, not a lot of research has been made in order to investigate the predictive value of CD62P
and P10 on the efficacy of HD in treating ESRD so far. Thus, this study aims to explore the correlation of CD62p, P10 and HD efficacy, so as to search for novel biological markers in prediction of the HD efficacy in patients with ESRD.
| ME THODS

| Ethics statements
This study was approved by the Institutional Review Board of Zhongda Hospital Southeast University. The written consent was obtained from each eligible participant with their privacy respected before entering the study. The study protocol was in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Residual urine volume detection was conducted using the urethral catheterization method under the following procedures: an individually packaged disposable urethral catheter without balloon was used for catheterization under sterile conditions; the urethra was inserted 2-3 cm until there was an outflow of urine with enough pressure on the pubic bone in order to push out all remaining urine; the urethral catheter was later pulled out slowly, and the urine collected was measured using 50 mL and 10 mL counting cups.
| Study subjects
Next, the normalized protein catabolic rate (nPCR) was calculated using the formula: PCR (g/d) = 9.35GU + 11.
GU (mg/min) = C urea (mL/min); BUN (mg/mL) = (Urea [mg/mL] × 
| Therapeutic regimen
HD was performed on the patients using reusable dialyzers with the help of polysulfone membranes (BBraun, Aesculap AG, Tuttlingen, Germany). The low molecular weight heparin (LMWH, 3000 IU) was injected intravenously to patients before the procedure of HD, continuously pumped at the speed of 1000 IU/h during HD, which was 
| Observation parameters
Before the collection of blood samples from each patient before and after 6-month HD treatment, a series of parameters were observed, including the amount of blood urea nitrogen (BUN), serum creatinine (Scr), serum phosphorus, serum calcium, hemoglobin (Hb), plasma
albumin (ALB), triglyceride (TG), intact parathyroid hormone (iPTH)
and β2-microglobulin (β2-MG), platelet (PLT), fibrinogen, prothrombin time (PT), activated partial thromboplastin time (APTT), patients' dry weights as well as subjective improvements of fatigue, poor sleep, poor appetite, ostealgia, and uremic pruritus as illustrated in Table S1 (concluded from the questionnaires). The subjective evaluation scale (Table S1 ) was revised according to the measurement table of KDQOL-SF, 14 to better suit the intentions of the present study. Based on these criteria, both excellently and ordinarily effective groups were viewed as effective groups. Patients were assigned to the effective group or the ineffective group according to the outcome of the observation parameters.
| Determination of positive expression of CD62P and P10
Early morning, 2 mL of blood was, respectively, intravenously taken from an antecubital vein before and after the procedure of HD and to make statistical analysis. Measurement data were expressed by mean ± standard deviation (SD); comparisons were made between two groups using the independent samples t test and the paired CD62P (orP10) − positive platelets CD62P (orP10) − positive platelets + CD62P (orP10) − negative platelets × 100% − non-specific binding cells% Measurement data were expressed by mean ± standard deviation; comparisons were made between two groups using the independent samples t test and the paired samples t test. Enumeration data were demonstrated as ratios or percentages and were compared using the chi-square test.
samples t test. Enumeration data were demonstrated as ratios or percentages and were compared using the chi-square test; and the correlation analysis was later performed by Pearson's correlation coefficient; the specificity and sensitivity of CD62P and P10
in predicating HD efficacy in treating ESRD patients were assessed specifically using the receiver operating characteristic (ROC) curve and also the factors affecting the efficacy in treating ESRD patients were discussed by logistic regression analysis. P < 0.05 showed significant difference.
| RE SULTS
| Clinical characteristics of ESRD patients
A total number of 111 patients with the average age of 57.88 ± 14.01 years and 117 healthy subjects with an average age of 56.49 ± 12.22 years (Table 1) were recruited in the baseline study. patients were suffering from mild-to-moderate malnutrition, and 2 patients were suffering from severe malnutrition at baseline.
| HD treatment is effective to ESRD patients
Here, the biochemical indicators of patients suffering from ESRD were measured to evaluate the efficacy of HD treatment. The results suggested that after the 6-month HD treatment, PLT, PT, and serum calcium in patients were manifested without a significant difference (both P > 0.05); simultaneously BUN, Scr, serum phosphorus, TG, iPTH, fibrinogen, and β2-MG markedly decreased (all P < 0.05), while Hb, ALB, and APTT were increased substantially (both P < 0.05) ( Table 2 ).
Patients diagnosed with ESRD presented with relief or complete resolution of fatigue and were manifested with the symptoms such as poor sleep, bad appetite, ostealgia, uremic pruritus, and abnormal psychological condition, notably increased dry weight (52.56 ± 6.95 & 59.07 ± 7.85), and significantly lowered subjective evaluation score (7.69 ± 4.62 & 3.61 ± 1.50) after the 6-month HD treatment (all P < 0.05). These findings demonstrated that HD treatment is effective to ESRD patients.
| CD62P and P10 levels are decreased in ESRD patients after the 6 months of HD treatment
Subsequently, the CD62P and P10 levels in pre-and post-treatment patients were determined. As shown in Table 3 , healthy subjects were observed to have significantly lower CD62P and P10 levels as compared to the pre-treatment patients (both P < 0.05); the levels of CD62P and P10 decreased significantly in post-treatment patients in comparison with the pre-treatment patients (both P < 0.05). From these results, we could find that HD treatment contributes to reduced CD62P and P10 levels. TA B L E 2 Biochemical parameters of ESRD patients before and after 6-mo HD treatment
| Expression levels of CD62P and P10 are positively correlated with Scr, BUN, and subjective score
This study explores the relations between levels of CD62P and P10
and Scr, BUN and subjective score of the patients, respectively.
Statistical correlation of levels of CD62P and P10 expressions and
Scr, BUN and subjective score of all patients showed that CD62P
and P10 positively correlated with Scr, BUN, and subjective score. In other words, higher level of CD62P and P10 expressions would lead to higher Scr, BUN, and subjective score (Figure 1) . Thus, levels of CD62P and P10 are positively associated with Scr, BUN and subjective score can be drawn. in peripheral blood were all correlated with HD efficacy (P < 0.05) ( Table 4 ).
| D ISCUSS I ON
This study was primarily conducted in order to assess the correlation between the levels of CD62P and P10 expressions and the efficacy of HD in patients suffering from ESRD, which could provide pre- Independent two sample t test was used for comparison between control group and pre-treatment group, and paired t test was performed for comparison between pre/post-treatment groups; ESRD, end-stage renal disease; *P < 0.05 vs pre-treatment patients in the case group; **P < 0.05 vs the control group.
F I G U R E 1
The levels of CD62P and P10 positively correlated with P10 and Scr, BUN, and subjective score. A, correlation analysis of CD62P and P10 with Scr; B, correlation analysis of CD62P and P10 with BUN; C, correlation analysis of CD62P and P10 with subjective score; Pearson's correlation analysis was applied for correlation analysis; Scr, serum creatinine; BUN, blood urea nitrogen The levels of CD62P and P10 expressions were observed to be higher in pre-treatment patients in contrast to the healthy subjects, but significantly decreased in post-treatment patients compared with the pre-treatment patients. After the 6-month HD treatment, the total amount levels of CD62P and P10 expressions were found to be significantly lower in the effective group compared to the ineffective group, thus, indicating CD62P and P10
could be used in the prediction of HD efficacy in treating ESRD.
CD62P, also named P-selectin or granule membrane protein 140
(GMP-140), is usually distributed in the alpha-granules of resting platelets and after the platelet activation it gets transferred to the cell surface. 17 The interaction of CD62P with P-selectin glycoprotein ligand-1 (PSGL-1) on the surface of the activated endothelial cells mediates tethering and rolling of leukocytes, which is the first step in the process of leukocyte extravasation and migration towards the sites of inflammation. 18 TSP, another alpha-granule content, is exposed on the surface of the stimulated platelets, and subsequently recognized by its monoclonal antibody P10. 9 TSPs are matricellular proteins which have some multifunctional effects through binding with cytokines, cell-surface receptors, as well as some other proteins. TSPs are all expressed in arterial lesions and play essential roles in vascular pathobiology. 19 Based on a previous study regarding the relationship between renal dialysis, platelet stimulation, and secretion markers, it is known that dialysis patients might present with decreased or increased levels of platelet stimulation. 20 Patients who have undergone HD treatment tend to have an inflammatory phenotype featured by enhanced activation of coagulation, platelets, and also fibrinolysis. 21 The major risk factors of cardiovascular disease in patients who have received HD treatment would also be increased due to the activation of chronic intermittent platelets which could be evaluated by the up-regulation of CD62P which always occurs for a short duration at the very beginning of HD. 22 Platelet activation could also induce thrombin generation and fibrin formation by promoting
The levels of CD62P and P10 correlated with the efficacy of HD detected using ROC. A, the ROC curve was plotted to evaluate the predictive value of CD62P for the efficacy of HD; B, the ROC curve was drawn to evaluate the predictive value of P10 for the efficacy of HD; HD, hemodialysis; ROC, receiver operating characteristic coagulation via the expression of phosphatidylserine as well as procoagulant factors. 23 Thus, the increased levels of CD62P and P10 could imply greater inflammatory responses and thrombosis, which was strongly associated with a blood hypercoagulable state 9 commonly occurring in many ESRD patients. Furthermore, the elevation of these CD62P and P10 levels during HD suggested that HD might promote platelet activation, increase alpha-granule protein retention and subsequently induce activation of coagulation cascade. 24 Therefore, significantly increased levels of CD62P and P10 expressions can induce platelet activation and coagulation.
It has been reported that HD could contribute to the increased levels of whole blood viscosity, plasma viscosity, red cell assembling index, as well as promoted platelet activation. 25, 26 CD62p
and P10 levels could be elevated after HD treatment owing to the promoted effects of HD on platelet activation 12 ; therefore, HD treatment should be employed with assisted drug treatment. In this study, shenshuaning capsule was introduced as an assisted drug, which decreased CD62p and P10 levels after HD treatment.
In our study, heparin is the most commonly used anticoagulant with anti-inflammatory effects. 27 Although heparin could lead to thrombocytopenia, bleeding episodes, and osteoporosis, [28] [29] [30] LMWH is effective to prevent venous thromboembolism antagonizing the advanced glycation end product axis. 
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